- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.10. | Glucotrack, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.09. | GlucoTrack files to sell 20.06M shares of common stock by selling shareholders | 1 | Seeking Alpha | ||
| 29.09. | Glucotrack, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.09. | GlucoTrack stock tumbles after issuing $3.6M convertible note | 2 | Investing.com | ||
| 11.09. | Glucotrack, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 11.09. | Glucotrack, Inc.: Glucotrack to Participate in the Q3 Virtual Investor Summit | 3 | GlobeNewswire (USA) | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 05.09. | Glucotrack, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 15.08. | Glucotrack GAAP EPS of -$9.62 | 1 | Seeking Alpha | ||
| 14.08. | Glucotrack to submit long-term CGM implant for FDA IDE this year | 1 | MassDevice | ||
| 14.08. | Glucotrack, Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 14.08. | GlucoTrack, Inc.: Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 266 | GlobeNewswire (Europe) | On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device... ► Artikel lesen | |
| 06.08. | Cardiac electrophysiologist Hirsh joins Glucotrack's clinical team | 1 | Investing.com | ||
| 06.08. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Glucotrack, Inc.: Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology | 177 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people... ► Artikel lesen | |
| 31.07. | Glucotrack, Inc.: Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 24.07. | Glucotrack, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 08.07. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Glucotrack, Inc.: Glucotrack Announces Repurchase of Series A Warrants | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,650 | -1,51 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,088 | +0,57 % | Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB AG: Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort | EQS-News: SYNLAB
/ Schlagwort(e): Strategische Unternehmensentscheidung
Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort
23.10.2025... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,024 | -9,16 % | NuGen Medical: Kurs explodiert nach wichtiger News! | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Announces Voting Results from Special Meeting of Stockholders / Evofem Shareholders Did Not Approve the Merger with Aditxt | -- Evofem Shareholders Did Not Approve the Merger with Aditxt --
-- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales... ► Artikel lesen | |
| UNIDOC HEALTH | 0,130 | +9,81 % | UniDoc als Aussteller bei der ANCI 2025 in Bologna von 12.-14. November | VANCOUVER, BC / 7. November 2025 / IRW-Press / UniDoc Health Corp. (CSE: UDOC) (FWB: L7T) (OTCQB:
UDOCF) ("UniDoc" oder das "Unternehmen") ist bei der 42. Jahresversammlung der ANCI (Associazione... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf | BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,344 | +0,58 % | Co-Diagnostics explores strategic options for Indian joint venture | ||
| EMPOWER CLINICS | - | - | Empower Clinics Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
| QUIDELORTHO | 18,500 | 0,00 % | QuidelOrtho Corporation: QuidelOrtho Reports Third Quarter 2025 Financial Results | ? Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ? ... ► Artikel lesen | |
| VERU | 2,470 | -0,80 % | Veru Inc.: Veru to Present Two Abstracts at ObesityWeek 2025 | ||
| QUEST DIAGNOSTICS | 154,45 | +1,05 % | ROUNDUP: Quest Diagnostics Cuts FY25 EPS View, But Lifts Adj. EPS, Revenue Forecast Above Street | WASHINGTON (dpa-AFX) - Quest Diagnostics Inc. (DGX), while reporting higher third-quarter results above market estimates, on Tuesday trimmed fiscal 2025 earnings view on a reported basis. However... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update | BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated... ► Artikel lesen | |
| SENSEONICS | 5,277 | -1,24 % | Senseonics down as 2025 guidance trails consensus | ||
| RADNET | 67,00 | -2,19 % | RadNet Q3 2025 Earnings Preview |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.